What's hotT!

What's Hot

The Great Debate: AI in Rheumatology

Drs. Mrinalini Dey, Jeffrey Curtis and Jinoos Yazdany

RA: Inject the Steroids

Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the 2025 ACR Convergence meeting in Chicago.

Watch video →

ACR2025 CAR-T Topic Panel

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping CAR-T practice right now. Panelists: Drs. Al Kim, Philip Mease, Yuz Yusof, Akhil Sood, and Jack Cush.

Watch video →

Tapering in SELECT GCA: Steroids are the Problem

Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at the 2025 ACR Convergence meeting in Chicago.

Watch video →

Specialized Biomarkers in PsA

Dr. Elaine Husni reports on abstract 0111 (Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures).

Watch video →

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA

At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.

Day 4 Recap: ACR Convergence 2025 Highlights

Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.

Watch video →

Weight Loss as a Therapeutic Goal in Psoriatic Arthritis

Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.

ACR 2025 - Day 3 Report

Day 3 in Chicago is hump day, the last big full day of presentations and posters. The day began with an 8AM plenary session, which brings me to the first of my three notables from today:

The Great Debate – Who Really Won?

My favorite session at ACR Convergence is often the “Great Debate.” The debate this year also evaluated one of my favorite topics – ultrasound in giant cell arteritis (GCA). More specifically, it asked the question of whether biopsy or ultrasound should be the preferred modality for diagnosing GCA.

What's the latest in PsA?

Dr. Peter Nash highlights key studies presented at the 2025 ACR Convergence meeting.

Watch video →

Is it All About the Weight Loss?

Dr. Jeffrey Curtis discusses two abstracts about the use of GLP-1 drugs and their impact beyond weight loss.

Watch video →

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.

Secrets and Pearls in Rheumatology

Dr. Janet Pope reports on secrets and pearls in rheumatology, from a session presented at the 2025 ACR Convergence meeting in Chicago

Watch video →

Perspectives on CAR T Therapy

Dr. Philip Mease offers his perspective on and takeaways from CAR-T therapy studies presented this week at the 2025 ACR Convergence meeting in Chicago.

Watch video →

The Long View of Diagnostic Delay in Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.

When the Back Hurts: uncovering BASDAI drivers in PsA

Dr. Elaine Husni reports on abstract 1426 (Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis).

Watch video →

Spondyloarthritis: The CLASSIC Study

Dr. Atul Deodhar reports on plenary session abstract 0854 (The ASAS and SPARTAN Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study).

Watch video →

Janet Pope Janetbirdope

4 months 1 week ago

#IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We

David Liew drdavidliew

4 months 1 week ago

Can a Fitbit track RA? This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic. Maybe instead of asking about our patients mobility and sleep, we should be measuring it? #ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2

https://x.com/drdavidliew/status/1983227402605211728/photo/1

Mrinalini Dey DrMiniDey

4 months 1 week ago

#1751 In early RA, higher disease activity, inflammation & older age linked to more ILD changes on machine-learning chest CT. Even subtle QCT abnormalities correlated with reduced lung function pointing to early inflammatory pathways in RA-ILD. @RheumNow #ACR25

David Liew drdavidliew

4 months 1 week ago

Are the clues of RA there in the EMR, before the diagnosis is made? Jina off-the-shelf AI with subsequent retraining found the digital fingerprint of RA in @MayoClinic medical notes, years before formal diagnosis. The clues are there #ACR25 ABST2260 @MyasoedovaElena @RheumNow https://t.co/onGlKUmefd

https://x.com/drdavidliew/status/1983225667119419748/photo/1

Mike Putman EBRheum

4 months 1 week ago

Adverse events from avacopan the WHO pharmacovigilence database (VigiBase) Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz

https://x.com/EBRheum/status/1983225627403563379/photo/1

Richard Conway RichardPAConway

4 months 1 week ago

Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356 https://t.co/bImzTA7uUC

https://x.com/RichardPAConway/status/1983225499255185474/photo/1

Antoni Chan MD (Prof) synovialjoints

4 months 1 week ago

In a 4-year study of 85 SpA patients, ChatGPT-4o matched SPSS in analyzing NLR/PLR trends. Outputs were identical, but ChatGPT offered faster interpretation and clinical context, highlighting AI’s potential to streamline early-stage research. Abstract#2354 @RheumNow #ACR25 https://t.co/W3pPQijPBD

https://x.com/synovialjoints/status/1983224744808984704/photo/1

Jiha Lee JihaRheum

4 months 1 week ago

In the CLOSE-UP study of UPA in RA - 61% in remission with responses sustained to 24 mo - Benefit consistent irrespective of prior DMARD use - No new safety signals @RheumNow #ACR25 Abstract#2281

David Liew drdavidliew

4 months 1 week ago

Infection vs steroid sparing in PMR/GCA/AAV studies with steroid-sparing Rx GiACTA (1, top right) aside, - low infection rates - the more steroid saved, the less the infection risk Infection risk in vasculitis is driven by steroid, not DMARD #ACR25 ABST2526 @RheumNow https://t.co/UprbxUQyQC

https://x.com/drdavidliew/status/1983221326518026404/photo/1

Md Yuzaiful Md Yusof Yuz6Yusof

4 months 1 week ago

#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4

https://x.com/Yuz6Yusof/status/1983220916264771657/photo/1

Richard Conway RichardPAConway

4 months 1 week ago

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. Progressive ILD in 23%. Similar to the numbers progressing on baricitinib by same group. Previous MTX treatment appears to REDUCE risk (OR 0.45). Disease activity increases risk (OR 1.29). @RheumNow #ACR25 Abstr#2265 https://t.co/0tl0kGgm5p

https://x.com/RichardPAConway/status/1983218705136800239/photo/1

Md Yuzaiful Md Yusof Yuz6Yusof

4 months 1 week ago

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

Jiha Lee JihaRheum

4 months 1 week ago

Starting biologic early could save more than joints. In 329 RA pts, first-line anti-TNF reduced testing and hospitalization costs vs csDMARDs across Europe. Earlier targeted therapy pay off in outcomes and economics. @RheumNow #ACR25 Abstract#2271 https://t.co/zZ32CpT36d

https://x.com/JihaRheum/status/1983217698508013990/photo/1

sheila RHEUMarampa

4 months 1 week ago

ROC-SpA study assessed whether changing to an IL-17Ai was superior to rotating to a 2nd TNFi in axSpA pts who failed on a 1st TNFi At wk 24, no significant diff in ASAS40 rates bet the 2 groups IL-17Ai not superior to a 2nd TNFi Rotate or change? #ACR25 @Rheumnow AbsLB09 https://t.co/4EtNEFTSN9

https://x.com/RHEUMarampa/status/1983217242008388002/photo/1

sheila RHEUMarampa

4 months 1 week ago

Data from this retrospective cohort study by Alomari et al show that SLE pts on SGLT2is ⬇️rates of PulHPN (OR 0.79) ⬇️all-cause mortality (0.49) ⬇️hospitalizations (OR 0.56) ⬇️LN (OR 0.4) vs non-SGLT2i users(p<0.001) Impt role of SGLT2i as adjunct tx #ACR25 @RheumNow Abs2438 https://t.co/NQJTzQwRCt